Arrowhead Research Corporation
 
insert therapeutics unidym tego bio sciences science research anti-cancer drugs RNAi therapeutics carbon-based electronics nanotechnology arrowhead pasadena california nasdaq arwr nanotechnology arrowhead pasadena california nasdaq arwr
PRESS RELEASE
June 14, 2010
Investor Relations Contacts:

Brandi Floberg
The Piacente Group
212-481-2050
ir@arrowres.com

 


ARROWHEAD TO REJOIN THE RUSSELL MICROCAP INDEX


PASADENA, Calif. — June 14, 2010– Arrowhead Research Corporation (NASDAQ: ARWR) today announced that it will join the Russell Microcap® Index when Russell Investments reconstitutes its family of U.S. indexes, according to a preliminary list of additions posted June 11 on www.russell.com. The final 2010 reconstitution of the Russell Indexes will take place after the market closes on June 25, 2010 and final membership lists will be posted on June 28 at: http://www.russell.com/Indexes/membership/default.asp.

"Being included in the Russell Index's reconstitution is a validation of the progress we have made over the last year. As we continue to execute on our growth strategy, we believe our membership will be a valuable tool to help raise our investment profile in the financial community," said Dr. Christopher Anzalone, Chief Executive Officer.

Russell Indexes are widely used by investment managers and institutional investors for both index funds and as benchmarks for passive and active investment strategies. The Russell Microcap Index comprises the smallest 1,000 securities in the Russell 2000® Index, plus the next 1,000 companies, based on a ranking of all U.S. equities by market capitalization. The Microcap Index was designed to offer managers and other investors a comprehensive, unbiased barometer to compare their performance against the genuine microcap marketplace of stocks.

The list of preliminary additions and deletions to the Russell Indexes can be found at: http://www.russell.com/indexes/membership/Reconstitution/Reconstitution_changes.aspx.

 




About Arrowhead Research Corporation

Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its subsidiaries and investments. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries; Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies.



Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.